Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

29 Oct 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Histone Deacetylase Inhibitors Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30420752
DOI: 10.1038/s41591-018-0233-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaPMID 30420752Read ↗

EFFICACY OF VENETOCLAX AND AZACITIDINE FOR TARGETING LEUKEMIC STEM CELL IN ACUTE MYELOID LEUKEMIASemantic proximity Read ↗

Myeloid differentiation-associated autophagy drives venetoclax resistance in AMLSemantic proximity Read ↗

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity Read ↗

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity Read ↗

Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial CalciumSemantic proximity Read ↗

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity Read ↗

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemiaSemantic proximity Read ↗

Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.Semantic proximity Read ↗

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity Read ↗

Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.